Neurocrine Free Cash Flow Operating Cash Flow Ratio from 2010 to 2024

NBIX Stock  USD 136.69  3.64  2.74%   
Neurocrine Biosciences Free Cash Flow Operating Cash Flow Ratio yearly trend continues to be fairly stable with very little volatility. Free Cash Flow Operating Cash Flow Ratio will likely drop to 0.81 in 2024. During the period from 2010 to 2024, Neurocrine Biosciences Free Cash Flow Operating Cash Flow Ratio regression line of annual values had r-squared of  0.18 and arithmetic mean of  1.02. View All Fundamentals
 
Free Cash Flow Operating Cash Flow Ratio  
First Reported
2010-12-31
Previous Quarter
0.92741729
Current Value
0.81
Quarterly Volatility
0.31609102
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Neurocrine Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Neurocrine Biosciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 22.4 M, Interest Expense of 7.4 M or Selling General Administrative of 894.2 M, as well as many indicators such as Price To Sales Ratio of 6.48, Dividend Yield of 0.0 or PTB Ratio of 6.13. Neurocrine financial statements analysis is a perfect complement when working with Neurocrine Biosciences Valuation or Volatility modules.
  
Check out the analysis of Neurocrine Biosciences Correlation against competitors.
For more information on how to buy Neurocrine Stock please use our How to Invest in Neurocrine Biosciences guide.

Latest Neurocrine Biosciences' Free Cash Flow Operating Cash Flow Ratio Growth Pattern

Below is the plot of the Free Cash Flow Operating Cash Flow Ratio of Neurocrine Biosciences over the last few years. It is Neurocrine Biosciences' Free Cash Flow Operating Cash Flow Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Neurocrine Biosciences' overall financial position and show how it may be relating to other accounts over time.
Free Cash Flow Operating Cash Flow Ratio10 Years Trend
Slightly volatile
   Free Cash Flow Operating Cash Flow Ratio   
       Timeline  

Neurocrine Free Cash Flow Operating Cash Flow Ratio Regression Statistics

Arithmetic Mean1.02
Geometric Mean0.99
Coefficient Of Variation30.96
Mean Deviation0.16
Median0.95
Standard Deviation0.32
Sample Variance0.1
Range1.3461
R-Value(0.42)
Mean Square Error0.09
R-Squared0.18
Significance0.12
Slope(0.03)
Total Sum of Squares1.40

Neurocrine Free Cash Flow Operating Cash Flow Ratio History

2024 0.81
2023 0.93
2021 0.91
2020 0.95
2019 0.9
2017 1.07
2016 1.04

About Neurocrine Biosciences Financial Statements

Neurocrine Biosciences investors use historical fundamental indicators, such as Neurocrine Biosciences' Free Cash Flow Operating Cash Flow Ratio, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Neurocrine Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Free Cash Flow Operating Cash Flow Ratio 0.93  0.81 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Neurocrine Stock Analysis

When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.